Sleep Apnea and Fatty Liver Disease: The Overlap Nobody Screens For
Pooled across 22 studies, three quarters of people with sleep-disordered breathing had fatty liver disease. The heterogeneity behind that figure is enormous, which matters — but the mechanism linking them is the same intermittent hypoxia that drives the rest of apnea's damage.
Three quarters of people with sleep-disordered breathing in the pooled data had fatty liver disease. That number is striking and it comes with heterogeneity high enough that you should treat it as a signal to investigate rather than a statistic to quote.
Both conditions are common, both are driven by weight, and almost nobody is screened for one while being treated for the other.
What the evidence shows
A 2026 systematic review and meta-analysis in Frontiers in Medicine, registered on PROSPERO and graded with GRADE, pooled 22 articles examining sleep-disordered breathing and liver outcomes in metabolic dysfunction-associated steatotic liver disease — MASLD, the condition formerly called NAFLD — and its inflammatory form, MASH.
- Pooled prevalence of MASLD or hepatic steatosis among patients with sleep-disordered breathing: 75.1% (95% CI 64.1 to 83.6%)
- Pooled prevalence of liver fibrosis or fibrosis risk: 13.9% (95% CI 6.0 to 29.0%)
- The presence of sleep-disordered breathing, or an increase in apnea severity, was significantly associated with liver outcomes
Now the caveat that has to travel with those numbers. Heterogeneity was I² = 94.8% for the steatosis figure and 96.8% for fibrosis. Those are extremely high. I² estimates the share of variation between studies that reflects real differences rather than chance, and values in the nineties mean the studies disagreed with each other substantially — different populations, different diagnostic methods, different thresholds.
A pooled prevalence of 75.1% with that much heterogeneity is better read as "very common across a varied set of clinical populations" than as "three in four of everyone with apnea."
Evidence tier 2. Registered protocol, GRADE assessment and 22 studies are methodological strengths. The heterogeneity, and the fact that prevalence studies cannot establish direction, are the limits.
Why would they be connected?
The review names the pathways: intermittent hypoxia, oxidative stress, inflammation, and metabolic dysfunction.
The hypoxia route is the one specific to apnea rather than to obesity. Repeated cycles of desaturation and re-oxygenation through the night produce oxidative stress and an inflammatory response, and the liver — which receives a large share of cardiac output and does most of the body's metabolic work — is exposed to all of it. In animal models, intermittent hypoxia alone worsens hepatic steatosis and inflammation independently of diet.
The other pathways are shared rather than specific. Obesity, insulin resistance and metabolic syndrome cause both conditions, which is the honest limit on reading too much into co-occurrence. Snoring and type 2 diabetes · Weight and snoring.
Once again the measure implicated is oxygen rather than event count. Hypoxic burden.
What this means if you have one of them
If you have fatty liver and snore: hepatology and sleep rarely meet. Raised liver enzymes, a fatty liver on a scan done for another reason, or a MASLD diagnosis alongside snoring and daytime tiredness is a reasonable combination to raise. It costs a sentence at an appointment.
If you have sleep apnea: liver assessment is not part of standard apnea follow-up, and fatty liver is usually silent until it is not. Routine liver enzymes are a crude screen — they can be normal in significant disease — but they are a starting point, and fibrosis risk scores calculated from ordinary blood results exist.
The fibrosis number is the one that matters clinically. Steatosis alone is common and frequently stable. Fibrosis is the step that predicts outcomes, and 13.9% of this population had it or were at risk of it.
And the shared lever is the obvious one. Weight loss improves both conditions through overlapping mechanisms, and it is the only intervention here that acts on both at once. Tongue fat and sleep apnea.
What this does not show
It does not show that apnea causes fatty liver. Prevalence studies establish co-occurrence, and the enormous shared confounder — obesity — is sitting in the middle of both.
It does not show that treating apnea improves liver outcomes. That would need trials with liver endpoints, and this review is not that.
And it does not change what to do about the breathing. No consumer product treats obstructive sleep apnea. If you have witnessed pauses, gasping arousals, morning headaches or sleepiness that more sleep does not fix, the step is assessment. Snoring versus sleep apnea.